6EYO image
Deposition Date 2017-11-13
Release Date 2018-08-15
Last Version Date 2024-11-13
Entry Detail
PDB ID:
6EYO
Keywords:
Title:
Structure of extended IgE-Fc in complex with two anti-IgE Fabs
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.70 Å
R-Value Free:
0.28
R-Value Work:
0.24
R-Value Observed:
0.24
Space Group:
P 21 21 21
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Immunoglobulin heavy constant epsilon
Gene (Uniprot):IGHE
Chain IDs:A, B
Chain Length:327
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:8D6 Fab heavy chain
Chain IDs:C (auth: I), D (auth: H)
Chain Length:227
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:8D6 Fab light chain
Chain IDs:E (auth: M), F (auth: L)
Chain Length:218
Number of Molecules:2
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Structural basis for selective inhibition of immunoglobulin E-receptor interactions by an anti-IgE antibody.
Sci Rep 8 11548 11548 (2018)
PMID: 30069035 DOI: 10.1038/s41598-018-29664-4

Abstact

Immunoglobulin E (IgE) antibodies play a central role in the allergic response: interaction with FcεRI on mast cells and basophils leads to immediate hypersensitivity reactions upon allergen challenge, while interaction with CD23/FcεRII, expressed on a variety of cells, regulates IgE synthesis among other activities. The receptor-binding IgE-Fc region has recently been found to display remarkable flexibility, from acutely bent to extended conformations, with allosteric communication between the distant FcεRI and CD23 binding sites. We report the structure of an anti-IgE antibody Fab (8D6) bound to IgE-Fc through a mixed protein-carbohydrate epitope, revealing further flexibility and a novel extended conformation with potential relevance to that of membrane-bound IgE in the B cell receptor for antigen. Unlike the earlier, clinically approved anti-IgE antibody omalizumab, 8D6 inhibits binding to FcεRI but not CD23; the structure reveals how this discrimination is achieved through both orthosteric and allosteric mechanisms, supporting therapeutic strategies that retain the benefits of CD23 binding.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
Feedback Form
Name
Email
Institute
Feedback